Prestige Consumer Results During COVID Show Success From Shifting Entirely To Health Care

Sales growth for OTC drug brands during latest quarter contribute to Prestige increasing its full-year guidance for FY2022, which ends on 31 March, for revenues growing around 9% to between $1.075bn and $1.08bn.